115 results about "Tretinoina" patented technology

The invention provides retinyl sodium hyaluronate and a composition thereof, which are applied to the fields of cosmetics and medicines. The retinoyl sodium hyaluronate is characterized in that all-trans retinoic acid and 13-cis-retinoic acid are esterified with sodium hyaluronate according to a molar ratio of (1.5-3.0): 1, and the esterification degree is 1%-12%; the composition disclosed by the invention is characterized by comprising retinyl sodium hyaluronate and a polyhydric alcohol compound in a mass ratio of 1: (1-10). The sodium retinoyl hyaluronate has a remarkable effect of preventing and treating acne, and the composition is beneficial to improving the stability of the sodium retinoyl hyaluronate and prolonging the validity period of a raw material product of the sodium retinoyl hyaluronate. The retinyl sodium hyaluronate and the composition thereof can be used for preparing cosmetics and medical products for whitening, resisting aging, controlling oil and removing acnes.

The invention relates to application of a retinoic acid compound in preparation of a medicine for treating and / or preventing glioblastoma. Compared with the prior art, the retinoic acid compound (1uM, 5uM) group has the advantages that the tumor inhibition rate of a glioblastoma organ is higher than that of an apatinib (1uM, 5uM) group, and is higher than that of an apatinib (1uM, 5uM) group. The subcutaneous tumor inhibition rate of glioblastoma cells of a retinoic acid compound (0.5 mg / kg and 5mg / kg) group is higher than that of an apatinib (32.5 mg / kg) group, and is higher than that of the apatinib (32.5 mg / kg) group in tumor pathological blood vessel inhibition rate. Therefore, the medicine (retinoic acid compound) for treating and (or) preventing the glioblastoma has a remarkable treatment and (or) preventing effect on the glioblastoma.

The invention discloses a sequential anti-tumor strategy based on combination of improved tumor microenvironment (TME) and CAR T and application of the sequential anti-tumor strategy, belongs to the technical field of biological medicine, and particularly relates to a sequential anti-tumor strategy based on combination of improved tumor microenvironment (TME) and CAR T. According to the strategy, tumor fibrosis and an acidic microenvironment are improved at the same time by applying a tumor-associated fibroblast (CAF) targeted drug and a proton pump inhibitor, and then sequential injection of CAR T is performed for combined treatment of solid tumors. Wherein the CAF targeting drug is selected from all-trans retinoic acid, calcipotriol, losartan and minetil, the proton pump inhibitor is selected from lansoprazole, omeprazole, pantoprazole, rabeprazole and esomeprazole, and the CAR T receptor or ligand is selected from mesothelin, protein tyrosine kinase 7, NKG2D, CD47, B7-H3, MUC1 and HER2; the sequential administration strategy firstly destroys a compact physical barrier of a tumor microenvironment, improves acidity of a tumor site, ensures infiltration, survival and proliferation of CAR T at the tumor site, and then utilizes specificity of CAR T to inhibit growth of solid tumors in a targeted manner, especially triple negative breast cancer with a high malignancy degree.

The present invention provides A ceramide compound, comprising: a structure of general formula I or an enantiomer or diastereomer of general formula I:in which:R1 is selected from the condensation residues of ferulic acid, sinapic acid, abscisic acid, sotretinoin, tretinoin, fusidic acid, royal jelly acid, sorbic acid, caffeic acid or trans-cinnamic acid;R2 is selected from one of the following structures:—C15H29, —C15H31, —C15H27, —CHOHC14H27, —CHOHC14H29.The present disclosure also provides a ceramide compound containing conjugated carboxylic acid, preparation method therefor and application thereof. The invention reacts functional carboxylic acid with sphingosine base to obtain a class of ceramide compound with novel structure. The introduction of physiologically active molecular fragments of functional carboxylic acids into ceramides will enhance the original efficacy of this type of molecules and also improve the physical and chemical properties of ceramide compound. For example, improving the antioxidant properties of ceramide compound.

An in vitro method for constructing a human vaginal epithelial model, which uses two stages of submerged culture and air-liquid surface culture to form a multilayered in vitro 3D model. During the submerged culture process, a low concentration of Ca 2+ (0.7~1.5mM) prevents the differentiation of vaginal epithelial cells; vitamin D is added to ensure that there are enough epithelial cells to maintain cell differentiation in the subsequent gas-liquid culture stage. In the gas-liquid interface culture stage, all-trans retinoic acid and 17 β-estradiol are added to the differentiation medium, among which all-trans retinoic acid can inhibit the continuous keratinization of vaginal epithelial cells and prevent excessive keratinization to form a stratum corneum. 17 β-estradiol enhances the barrier function of the vaginal epithelial model. Therefore, the joint use of all-trans retinoic acid and 17 β-estradiol can ensure that the epithelial layer of the vaginal epithelial model cannot differentiate into a mature stratum corneum, but still has a certain barrier function.

The invention provides application of retinoic acid in preparation of a medicine for treating vascular calcification, and belongs to the technical field of medicines. The early warning and treatment effects of retinoic acid on vascular calcification are provided for the first time, a new source is provided for preparing the medicine for early warning and / or treating vascular calcification, and meanwhile the new medicinal value of retinoic acid is explored. Cardiovascular calcification and vascular smooth muscle cell calcification are relieved by supplementing retinoic acid in vivo and in vitro, and the feasibility that retinoic acid can be used as a potential medicine for treating vascular calcification is prompted. The retinoic acid content is in negative correlation with the coronary artery calcification integral of the human body and the calcification severity degree, and it is prompted that the retinoic acid content can serve as an early warning index of cardiovascular calcification and the severity degree.

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1), a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and all-trans retinoic acid or a pharmaceutically acceptable salt thereof and the use of the combination therapies for the treatment of cancer.

The invention relates to the technical field of biomedicine, in particular to a novel target spot for resisting chikungunya virus infection and application. According to the invention, human colon cancer cells (HCT116) are taken as target cells, and retinoic acid-induced protein expression of the target cells is reduced by adopting a gene knockout technology, so that host factors capable of effectively inhibiting CHIKV infection of the human colon cancer cells are found, and the purpose of blocking CHIKV infection from the source is achieved. It is found that retinoic acid induced protein 16 (RAI16) plays an important role in CHIKV infected HCT116 cells, and CHIKV infection can be obviously promoted by down-regulating expression of RAI16. The invention provides an application of RAI16 in preparation of a medicine for preventing or treating chikungunya virus infection, and provides a new target spot and a treatment scheme for clinically preventing and treating fever, arthralgia, arthrocele, muscular pain, headache, nausea, fatigue, rash and other diseases caused by CHIKV infection.

The invention provides application of AhR in regulation and control of ALDH1A3 and synthesis of retinoic acid. Specifically, the invention provides an application of a reagent in preparation of a product, the reagent is used for regulating and controlling AhR or an AhR signal channel, and the product is used for at least one of the following: regulating and controlling ALDH1A3; regulating and controlling synthesis of retinoic acid; the expression of skin barrier function related genes is regulated and controlled. The inventor provides the application by utilizing the relationship between AhR and ALDH1A3, the relationship between ALDH1A3 and retinoic acid and the relationship between retinoic acid and the skin barrier function, and when an AhR or AhR signal channel is regulated and controlled, the generation of ALDH1A3, retinoic acid synthesis and skin barrier function gene transcription can be regulated and controlled at the same time.

The invention belongs to the technical field of veterinary vaccine adjuvants, and particularly relates to an intestinal tract targeted saccharum alhagi polysaccharide-aluminum adjuvant Pickering emulsion as well as a preparation method and application of the intestinal tract targeted saccharum alhagi polysaccharide-aluminum adjuvant Pickering emulsion. The intestinal tract targeted saccharum alhagi polysaccharide-aluminum adjuvant Pickering emulsion is AHPPE, the AHPPE is formed by mixing an oil phase and a water phase, and the volume ratio of the oil phase to the water phase is 1: (9-13); the oil phase is prepared from the following raw materials: squalene and retinoic acid; the mass ratio of the squalene to the retinoic acid is 1: (0.7-0.8); the water phase is prepared from the following raw materials: saccharum alhagi polysaccharide and aluminum hydroxide; the mass ratio of the saccharum alhagi polysaccharide to the aluminum hydroxide is 1: (10-13). According to the preparation method provided by the invention, the problems that retinoic acid is difficult to dissolve in water and the metabolism speed of saccharum alhagi polysaccharide is high are solved, and meanwhile, an organism can be induced to generate effective systemic immunity and intestinal mucosa immunity by injecting AHPPE.

The present invention provides a retinoic acid derivative that has high stability and water solubility. The present invention relates to a carboxylic acid ester compound of trehalose or a derivative thereof and retinoic acid.

The present invention relates to a conjugate compound comprising 13-cis-retinoic acid and vitamin C, and its pharmaceutically acceptable salts thereof. The present invention also relates to a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier. The present compound has a much better water solubility than that of retinoic acid, and thus reduces an effective dosage of retinoic acid and minimizes side effect. The present compound increases the efficiency and concentration of 13-cis-retinoic acid to across the cell membrane into the cell. The present compound is useful in treating cancer such as pancreatic cancer.

The invention provides a special culture medium for prostate cancer organoid and a culture method thereof, and belongs to the technical field of biological medicines. The special culture medium for the prostatic cancer organoid is composed of a basic culture medium and a culture additive, and the basic culture medium does not contain exogenously added Noggin recombinant protein and R-spondin recombinant protein. The culture additive is prepared from a basic fibroblast growth factor, a keratinocyte growth factor, a fibroblast growth factor 10, insulin, a p38MAPK signal channel inhibitor, an insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, a ROCK kinase inhibitor, retinoic acid, interleukin 6, prostaglandin E2, a eriocin and androgen. According to the special culture medium for the prostatic cancer organoid, the culture success rate is increased while the cost is reduced.

The present application provides a kind of retinyl hyaluronate sodium and its composition applied in the field of cosmetics and medicine.The retinyl hyaluronate sodium of the present application is characterized by all-trans retinoic acid and 13-cis retinoic acid esterification with sodium hyaluronate in a ratio of 1.5-3.0:1 (molar ratio), and the esterification degree is 1%-12%;The composition of the present application is characterized by retinyl hyaluronate sodium and polyol compound in a ratio of 1:1-10 (mass ratio).The retinyl hyaluronate sodium of the present application has significant effect in preventing and treating acne, and the composition is beneficial to improve the stability of retinyl hyaluronate sodium, prolong the shelf life of retinyl hyaluronate sodium raw material product.The retinyl hyaluronate sodium and its composition of the present application can be used for preparing whitening, anti-aging, oil control and acne-removing cosmetics and medical products.

Provided are: a method for producing a spinal cord organoid from a pluripotent stem cell in vitro, the method comprising (1) a step for culturing a human pluripotent stem cell in a culture medium that contains a ROCK inhibitor and a Wnt signal activator but does not substantially contain a TGFβ inhibitor or a BMP signal inhibitor, (2) a step for further culturing the cell obtained in step (1) in a culture medium that contains a retinoic acid receptor agonist and a hedgehog signal activator, and (3) a step for further culturing the cell obtained in step (2) in a culture medium that does not substantially contain a TGFβ inhibitor, a BMP signal inhibitor, a retinoic acid receptor agonist, or a sonic hedgehog stimulator to obtain a spinal cord organoid; and a spinal cord organoid obtained by the method. The spinal cord organoid according to the present application comprises at least a portion of the dorsal side of the spinal cord and a ventral region of the spinal cord.

The present application is directed to compositions comprising microcapsules comprising encapsulated tretinoin, wherein the microcapsule size is less than 50 μm; and to methods of use thereof.

The invention provides a drug-loaded gelatin nanogel, a bionic nanogel, a preparation method of the drug-loaded gelatin nanogel, a preparation method of the bionic nanogel, a combined drug and application of the bionic nanogel, and belongs to the technical field of biological medicine. According to the invention, all-transretinoic acid, pirfenidone and gelatin react to form drug-loaded gelatin nanogel, and the drug-loaded gelatin nanogel can synergistically inhibit the activation of pancreatic stellate cells and block a fibrosis-promoting signal channel, so that the reversion of a pancreatic cancer fibrosis microenvironment is realized; meanwhile, the activated pancreatic stellate cell membrane is coated with the drug-loaded gelatin nanogel to construct the bionic nanogel, so that the bionic nanogel has active targeting property, and the delivery efficiency and the treatment effect of the drug are remarkably improved; and the drug-loaded gelatin nanogel, the bionic nanogel and the chemotherapeutic drug are combined for treating pancreatic cancer, so that a remarkable anti-tumor effect is achieved, and the combined treatment of the bionic nanogel and gemcitabine has a synergistic anti-tumor effect. The gel provided by the invention realizes effective regulation and control of a pancreatic cancer dense fibrosis microenvironment, and provides a feasible new strategy for treatment of pancreatic cancer.

The embodiment of the invention discloses application of a composition in preparation of a retinoic acid receptor gamma agonist and an external skin care product containing the composition. The composition comprises one or more of cyasterone, geraniin and corilagin. The embodiment of the invention further discloses application of the composition in preparation of a retinoic acid binding protein 2 agonist. The invention also discloses an application of the prepared retinoic acid receptor gamma agonist or retinoic acid binding protein 2 agonist in preparation of a photoaging skin cell protection composition.

The invention discloses an application of an activator combined by one or more genes / proteins in preparation of drugs for treating hypertrophic scars, and belongs to the technical field of biological medicines. In order to solve the problem that when retinoic acid cream is used for preparing hypertrophic scars, a specific mode and an action target of a retinoic acid signal channel for regulating and controlling fibroblasts are not disclosed yet, the action target and a regulation and control mechanism of ATRA for regulating and controlling fibroblast activation and glucose metabolism remodeling are explored through in-vivo and in-vitro experiments; and on the basis of a Cre-loxP system, the function of the target gene is verified. Researches in the invention show that ATRA promotes transcription of HIC1 and inhibits transcription and expression of TGF-beta1 by activating RAR alpha on one hand, and ATRA promotes transcription of HIC1 and inhibits transcription and expression of TGF-beta1 on the other hand; on the other hand, the transcription of PCK1 and PCK2 is promoted, so that the proliferation and abnormal activation of HSFs are reduced, and the occurrence and development processes of hypertrophic scars are finally inhibited. The conclusion provides a sufficient theoretical basis for inhibiting hypertrophic scar formation by ATRA.

The present invention provides an application of a reagent for detecting retinol metabolites in the preparation of a tool for diagnosing and / or treating pneumoconiosis, and relates to the field of biomedical technology. The present invention verifies that retinol metabolism disorders and all-trans retinoic acid deficiency are closely related to the occurrence of pneumoconiosis, and therefore proposes to use retinol and all-trans retinoic acid as biomarkers for screening pneumoconiosis and apply them to the preparation of related products for diagnosing pneumoconiosis; at the same time, all-trans retinoic acid intervention for pneumoconiosis can effectively slow down the progression of pneumoconiosis, and therefore proposes for the first time to use all-trans retinoic acid as a drug for treating pneumoconiosis.

The invention discloses a docetaxel-loaded retinoic acid derivative polymer micelle and a preparation method thereof, and belongs to the technical field of biological medicines. The polymer micelle is prepared from docetaxel and a retinoic acid derivative polymer mPR. The preparation method comprises the following steps: mixing and dispersing the polymer mPR and docetaxel into a drug film, and hydrating with a proper medium to prepare the polymer micelle. The docetaxel polymer micelle disclosed by the invention is high in encapsulation efficiency, high in drug loading capacity, high in stability and relatively good in curative effect and safety.

The present invention provides high drug load and high dose oral pharmaceutical compositions of isotretinoin with low fill weights and smaller capsules. The present invention further provides processes for the preparation of the disclosed oral pharmaceutical compositions, and methods for treating diseases and conditions such as skin disorders, including acne, by orally administering the disclosed oral pharmaceutical compositions to a patient in need thereof.

Provided herein are novel reprogrammed smooth muscle cells (rSMCs) and methods of making and using the cells for the treatment of ischemia. The rSMCs are produced by culturing a fibroblast with an all-trans-retinoic acid (ATRA) under conditions that produce the rSMC from the fibroblast, wherein the fibroblasts are genetically modified to overexpress myocardin. The rSMCs offer advantages over currently available regenerative vascular therapies by promoting vascular perfusion in a recipient subject. In particular, the rSMCs can increase neovascularization of both small and large vessels.

Described herein are retinoid compositions comprising (a) a retinoid preferably a C20-deuterated vitamin A that inhibits dimerisation to N-retinylidene-N-retinylethanolamine (A2E), (b) a lipid excipient preferably an omega-3 fatty acid comprising eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), and (c) a surfactant, wherein the compositions increase the bioavailability of the retinoid in a subject, and methods of using such retinoid compositions for treating eye conditions including macular degeneration.

Described herein is a method of treating cancer by administering an effective concentration of liposomes of all-transretinoic acid.

The invention discloses a dual-regulation pharmaceutical composition for sepsis treatment, a preparation method and application, and belongs to the technical field of biological medicine, and the pharmaceutical composition comprises doxorubicin liposome, all-trans retinoic acid phospholipid complex nanoparticles and antibiotics. Preferably, the doxorubicin liposome is prepared from the sialic acid modified doxorubicin liposome, the sialic acid modified all-trans retinoic acid phospholipid compound nanoparticles and meropenem. Dynamic monitoring of myeloid-derived suppressor cells MDSCs and sialic acid binding immunoglobulin type lectin-E (SiglecE) positively expressed myeloid-derived suppressor cells, namely SiglecE + MDSCs cell subsets, in the middle and later periods of sepsis is used as an evaluation index of the immunosuppression state, and dual regulation and control of sepsis acute inflammation and immunosuppression are achieved. The method has remarkable advantages in the aspects of increasing the survival rate, precisely targeting immunosuppression, improving the drug delivery efficiency and the like, and a brand new solution is provided for clinical treatment of sepsis.

The present disclosure relates to the treatment of achondroplasia using retinoic acid receptor (RAR) antagonists.

This invention, entitled "A Method and Product for Pretreatment of Mesenchymal Stem Cells and Its Application in Stroke Drugs," belongs to the field of biotechnology. The technical problem to be solved is to improve the function and therapeutic effect of mesenchymal stem cells. The key technical solution is a method for pretreatment of mesenchymal stem cells, including: culturing cells using an activation medium, culturing cells using a directional medium, and culturing cells under hypoxic conditions using an adaptation medium; the activation medium contains complete medium, IFN-γ, TNF-α, and IL-1β; the directional medium contains complete medium, sodium valproate, 5-azacytidine, and all-trans retinoic acid; the adaptation medium is a complete medium containing basal medium and free of animal serum. The pretreatment method of this invention enhances the anti-inflammatory, neuroprotective, and angiogenic capabilities of mesenchymal stem cells, showing significant therapeutic effects on stroke, and since it does not use animal serum, it meets clinical requirements.

The application discloses a sequential anti-tumor strategy based on improvement of tumor microenvironment (TME) combined with CAR T and application thereof, and belongs to the technical field of biological medicine, which simultaneously improves tumor fibrosis and acid microenvironment by applying tumor-related fibroblast (CAF) targeting drugs and proton pump inhibitors, and sequentially injects CAR T combined therapy for solid tumors, wherein the CAF targeting drugs are selected from tretinoin, calcipotriol, losartan and minnelide, the proton pump inhibitors are selected from lansoprazole, omeprazole, pantoprazole, rabeprazole and esomeprazole, and the CAR T receptor or ligand is selected from mesothelin, protein tyrosine kinase 7, NKG2D, CD47, B7-H3, MUC1 and HER2; the sequential administration strategy first destroys the dense physical barrier of the tumor microenvironment, improves the acidity of the tumor site, ensures the infiltration, survival and proliferation of CAR T at the tumor site, and then targets and inhibits the growth of solid tumors, especially high-malignancy triple-negative breast cancer, by using the specificity of CAR T.

Disclosed are methods of accelerating development of new hair follicles in pluripotent stem cell-derived skin organoids. In particular, disclosed are methods of accelerating development of new hair follicles in skin organoids by adding one or more growth factors, such as FGF10, FGF20, BIO, ruxolitinib, tofacitinib, LDN193189, vitamin E, GDNF, retinoic acid, or IGF2. The growth factors are added to a culture of skin organoid at critical windows of time of the skin organoid development, such as after (or upon) the formation of epidermis and dermis in the skin organoid.